Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Full Of Hopes For Vyvanse Binge-Eating Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

First Phase II results in expansion program for the ADHD therapy show strong response in the eating disorder, but the company faces a regulatory challenge in gaining the first approval for the condition.

You may also be interested in...



Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating

Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.

Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating

Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.

Shire Wrings Life Out Of Adderall XR Despite Actavis Generic Launch

Branded Adderall XR will remain competitive, Shire CEO Angus Russell predicts during the company’s second quarter sales and earnings call, despite the launch of the first generic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel